Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy
- PMID: 11496233
- DOI: 10.1067/mai.2001.116984
Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy
Abstract
Background: Recent studies have demonstrated that bacterially derived immunostimulatory sequences (ISSs) of DNA can activate the mammalian innate immune system and promote the development of T(H)1 cells. Promotion of T(H)1 immunity by means of immunotherapy in allergic patients has led to the alleviation of symptoms that result from allergen-specific T(H)2 responses.
Objective: Our purpose was to investigate whether the T(H)1-enhancing properties of ISSs could be used to alter the T(H)2-dominated immune response of allergic PBMCs in vitro.
Methods: Ragweed protein-linked ISS (PLI) was generated from a specific, highly active 22-base ISS and Amb a 1, the immunodominant allergen in ragweed pollen, to combine the T(H)1-enhancing properties of ISSs with allergen selectivity, and its activity was investigated in PBMC cultures from subjects with ragweed allergy.
Results: PLI was markedly successful at reversing the dominant allergen-induced T(H)2 profile while greatly enhancing IFN-gamma production. Delivering ISSs in a linked form proved to be much more effective at modulating the resulting cytokine profile than delivering free ISSs in a mixture with unlinked Amb a 1. PLI also demonstrated cytokine-modulating properties, even when used to stimulate cells that had already been primed for 6 days with Amb a 1. The antigen specificity of the action of PLI was confirmed by the observations that PLI enhances Amb a 1--specific T-cell proliferation.
Conclusion: These data indicate that delivery of ISSs within an antigen-specific context exhibits potent cytokine-modulating activity and, combined with its reduced allergenicity, makes this molecule a strong candidate for use in improved immunotherapy applications.
Similar articles
-
Local induction of a specific Th1 immune response by allergen linked immunostimulatory DNA in the nasal explants of ragweed-allergic subjects.Allergol Int. 2009 Dec;58(4):565-72. doi: 10.2332/allergolint.09-OA-0108. Epub 2009 Sep 25. Allergol Int. 2009. PMID: 19776676
-
Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.J Allergy Clin Immunol. 2004 Jun;113(6):1144-51. doi: 10.1016/j.jaci.2004.03.003. J Allergy Clin Immunol. 2004. PMID: 15208597 Clinical Trial.
-
Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1.J Allergy Clin Immunol. 2006 Aug;118(2):504-10. doi: 10.1016/j.jaci.2006.05.001. Epub 2006 Jun 27. J Allergy Clin Immunol. 2006. PMID: 16890778
-
Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;(94):304-12; discussion 312-3. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003. PMID: 15119051 Review.
-
Molecular and cellular studies of human immune responsiveness to the short ragweed allergen, Amb a V.Eur Respir J Suppl. 1991 Apr;13:60s-67s. Eur Respir J Suppl. 1991. PMID: 1953919 Review.
Cited by
-
The dichotomy of pathogens and allergens in vaccination approaches.Front Microbiol. 2014 Jul 16;5:365. doi: 10.3389/fmicb.2014.00365. eCollection 2014. Front Microbiol. 2014. PMID: 25076945 Free PMC article. Review.
-
Novel adjuvants in allergen-specific immunotherapy: where do we stand?Front Immunol. 2024 Feb 23;15:1348305. doi: 10.3389/fimmu.2024.1348305. eCollection 2024. Front Immunol. 2024. PMID: 38464539 Free PMC article. Review.
-
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.J Virol. 2002 Nov;76(22):11387-96. doi: 10.1128/jvi.76.22.11387-11396.2002. J Virol. 2002. PMID: 12388699 Free PMC article.
-
Latest developments in the management of allergic rhinitis.Clin Rev Allergy Immunol. 2004 Dec;27(3):181-9. doi: 10.1385/CRIAI:27:3:181. Clin Rev Allergy Immunol. 2004. PMID: 15630154 Review.
-
Vaccine adjuvants: mode of action.Front Immunol. 2013 Jul 31;4:214. doi: 10.3389/fimmu.2013.00214. eCollection 2013. Front Immunol. 2013. PMID: 23914187 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous